

CORRIGENDUM

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, J Haessler, J Feather, A Hoering, P Moreau, X LeLeu, C Hulin, SK Klein, P Sonneveld, D Siegel, J Bladeé, H Goldschmidt, S Jagannath, JS Miguel, R Orłowski, A Palumbo, O Sezer, SV Rajkumar and BGM Durie on behalf of the International Myeloma Working Group

Leukemia (2012) 26, 1153; doi:10.1038/leu.2012.15

Correction to: *Leukemia* (2012) 26, 149–157; doi:10.1038/leu.2011.196

Since the publication of this paper, the authors have noticed that one of the author names in the appendix

was incorrectly listed as Hareth Nari. It should be listed as follows:

Hareth Nahi, Karolinska University Hospital, Stockholm, Sweden.

The authors apologise for any inconvenience caused.